View in EDS

Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.

Saved in:
Bibliographic Details
Title: Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
Authors: Fleisher AS; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Munsie LM; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Perahia DGS; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Andersen SW; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Higgins IA; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Hauck PM; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Lo AC; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Sims JR; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Brys M; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA., Mintun M; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.
Corporate Authors: PERISCOPE-ALZ Site Investigators; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.
Source: Neurology [Neurology] 2024 Mar 12; Vol. 102 (5), pp. e208061. Date of Electronic Publication: 2024 Feb 22.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-632X (Electronic) Linking ISSN: 00283878 NLM ISO Abbreviation: Neurology Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38386949
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fleisher+AS%22">Fleisher AS</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Munsie+LM%22">Munsie LM</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Perahia+DGS%22">Perahia DGS</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Andersen+SW%22">Andersen SW</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Higgins+IA%22">Higgins IA</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Hauck+PM%22">Hauck PM</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Lo+AC%22">Lo AC</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Sims+JR%22">Sims JR</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Brys+M%22">Brys M</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Mintun+M%22">Mintun M</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22PERISCOPE-ALZ+Site+Investigators%22">PERISCOPE-ALZ Site Investigators</searchLink>; From Eli Lilly and Company, Indianapolis, IN. Dr. A.C. Lo is currently at Kisbee Therapeutics, Cambridge, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220401060%22">Neurology</searchLink> [Neurology] 2024 Mar 12; Vol. 102 (5), pp. e208061. <i>Date of Electronic Publication: </i>2024 Feb 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lippincott+Williams+%26+Wilkins%22">Lippincott Williams & Wilkins </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0401060 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1526-632X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200283878%22">00283878 </searchLink><i>NLM ISO Abbreviation: </i>Neurology <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38386949
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1212/WNL.0000000000208061
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e208061
    Titles:
      – TitleFull: Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fleisher AS
      – PersonEntity:
          Name:
            NameFull: Munsie LM
      – PersonEntity:
          Name:
            NameFull: Perahia DGS
      – PersonEntity:
          Name:
            NameFull: Andersen SW
      – PersonEntity:
          Name:
            NameFull: Higgins IA
      – PersonEntity:
          Name:
            NameFull: Hauck PM
      – PersonEntity:
          Name:
            NameFull: Lo AC
      – PersonEntity:
          Name:
            NameFull: Sims JR
      – PersonEntity:
          Name:
            NameFull: Brys M
      – PersonEntity:
          Name:
            NameFull: Mintun M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 03
              Text: 2024 Mar 12
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1526-632X
          Numbering:
            – Type: volume
              Value: 102
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Neurology
              Type: main
ResultId 1